{
    "nct_id": "NCT03758989",
    "official_title": "A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma",
    "inclusion_criteria": "* Previously untreated limited stage non bulky DLBCL; defined as limited stage by routine staging criteria in lymphoma involving FDG-PET and bone marrow biopsies (the Lugano criteria)[21]\n* Patients with grade 3B follicular lymphoma and transformed indolent lymphoma are included\n* Ages â‰¥ 18\n* Measurable disease, assessable by radiographic examination with FDG-PET showing involvement\n* Access to archived or fresh/frozen tumor biopsies\n* No uncontrolled medical comorbidities\n* Adequate cardiac function (EF > or equal to 50%), no unstable angina\n* Adequate renal function (GFR > 60)\n* Adequate liver function (liver function tests should be no greater than 2 x upper limit of normal) including normal bilirubin levels, no greater than 2 x upper limit of normal unless patient has a history of Gilbert's disease\n* Adequate marrow reserves as indicated by complete blood count in the judgment of the treating investigator\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnancy, positive serum HCG within 28 days of enrollment, or breast-feeding\n* Bulky disease greater than 10 cm in any dimension",
    "miscellaneous_criteria": ""
}